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The CSF-470 cellular vaccine plus BCG and rhGM-CSF increased distant
metastases-free survival in cutaneous melanoma patients stages IIB-IIC-III relative
to medium dose IFN-α2b (CASVAC-0401 study). Patient-045 developed a mature
vaccination site (VAC-SITE) and a regional cutaneous metastasis (C-MTS), which were
excised during the protocol, remaining disease-free 36 months from vaccination start.
CDR3-TCRβ repertoire sequencing in PBMC and tissue samples, along with skin-DTH
score and IFN-γ ELISPOT assay, were performed to analyze the T-cell immune response
dynamics throughout the immunization protocol. Histopathological analysis of the
VAC-SITE revealed a highly-inflamed granulomatous structure encircled by CD11c+
nested-clusters, brisk CD8+ and scarce FOXP3+, lymphocytes with numerous Langhans
multinucleated-giant-cells and macrophages. A large tumor-regression area fulfilled the
C-MTSwith brisk lymphocyte infiltration, mainly composed of CD8+PD1+ T-cells, CD20+
B-cells, and scarce FOXP3+ cells. Increasing DTH score and IFN-γ ELISPOT assay
signal against the CSF-470 vaccine-lysate was evidenced throughout immunization.
TCRβ repertoire analysis revealed for the first time the presence of common clonotypes
between a VAC-SITE and a C-MTS; most of them persisted in blood by the end of
the immunization protocol. In vitro boost with vaccine-lysate revealed the expansion of
persistent clones that infiltrated the VAC-SITE and/or the C-MTS; other persistent clones
expanded in the patient’s blood as well. We propose that expansion of such persistent
clonotypes might derive from two different although complementary mechanisms:
the proliferation of specific clones as well as the expansion of redundant clones,
which increased the number of nucleotide rearrangements per clonotype, suggesting
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a functional antigenic selection. In this patient, immunization with the CSF-470 vaccine
plus BCG and rhGM-CSF induced a T-cell repertoire at the VAC-SITE that was able to
infiltrate an emerging C-MTS, which resulted in the expansion of a T-cell repertoire that
persisted in blood by the end of the 2-year treatment.
Keywords: cutaneous melanoma, CSF-470 vaccine, vaccination site, cutaneous metastasis, tumor infiltrating
lymphocytes, TCRβ repertoire
INTRODUCTION
Treatment of cutaneous melanoma (CM) has greatly improved
in recent decades due to two main discoveries. First, it was found
that tumors from about half of CM patients carry the driver
activating mutation V600E in the BRAF oncogene (1), for which
inhibitors such as vemurafenib (2), and dabrafenib (3) have been
designed. The use of such inhibitors, to which MEK inhibitors,
such as cobimetinib and trametinib, were later added, produced
good clinical results in stage-IV CM patients (4, 5) and more
recently in adjuvancy in stage-III CM patients (6). However, the
common development of drug resistance is the main drawback of
these treatments (7).
Second, different lines of research led to the discovery of
immune checkpoints, such as the CTLA-4/CD80-86 (8) and
PD1/PD-L1 (9) axes, whose roles are to turn-off antigen(Ag)-
stimulated lymphocytes, presumably to prevent over-activity.
Blocking those regulatory axes with Immune Checkpoint
Inhibitory (ICKI) monoclonal antibodies (MAbs) produced
impressive clinical results, both in advanced CM (10) and in
non-small cell lung carcinoma (11). Recently, the anti-PD1
pembrolizumab has been reported to be also effective as adjuvant
treatment in stage-III CM patients (12). The rationale behind
this clinical effect is that ICKI relieve CD8+ lymphocytes
from exhaustion, and since they are administrated without
any previous immune stimulation, it is assumed that anti-
tumor reactive lymphocytes already exist in cancer patients in
number enough so that previous stimulation is unnecessary.
However, evidence has been found that the clinical result of
ICKI is better in the measure that tumors are more heavily
infiltrated by lymphocytes; therefore, an increase in tumor-
reactive lymphocytes previous to ICKI administration would be
beneficial (13).
We have demonstrated in a randomized Phase II adjuvant
study (CASVAC-0401, NCT01729663), that the CSF-470 cellular
vaccine in combination with BCG and rhGM-CSF, increased
Abbreviations: ABC, Avidin-Biotin-Peroxidase; Ags, antigens; BCG, Bacillus
Calmette Guerin; CM, cutaneous melanoma; C-MTS: cutaneous metastasis; DTH,
Delayed Type Hypersensitivity; FFPE, Formalin-fixed, paraffin-embedded; GZMB,
granzyme B; HE, hematoxylin-eosin; HLA, human leucocyte antigen; ICKI,
immune checkpoint inhibitors; IFN-α2b, interferon alpha 2b; IFN-γ, interferon-
gamma; LMGC, Langhans multinucleated giant cells; LN, lymph node; MAbs,
monoclonal antibodies; MIFC, markedly-increased frequency clones; MIRC,
markedly-increased redundant clones; PHA, Phytohemagglutinin-A; PBMC,
Peripheral blood mononuclear cells; Pt, patient; rhGM-CSF, recombinant human
granulocyte macrophage-colony stimulating factor; SLNB, sentinel lymph node
biopsy; TCRβ, T-cell receptor beta; TIL, tumor infiltrating lymphocytes; VAC-
SITE, vaccination site; VLF, very low frequency.
distant metastases-free survival in stages IIB, IIC, and III
CM patients with respect to medium dose IFN-α2b (14). In
the same study, it was demonstrated that T-cell reactivity
against vaccine Ags was maintained over the 2 years (2-
yr) treatment without signs of exhaustion. Besides, only low
numbers of T lymphocytes reactive to melanoma cells were
detected in blood before treatment, whereas after vaccination
they strongly increased (15). In a previous analysis of vaccinated
patient-006 from the CASVAC-0401 trial, an increase in tumor
infiltrating lymphocytes (TIL) in a cutaneous metastasis (C-
MTS) developing at the end of the immunization protocol was
observed. This lesion was infiltrated with a T-cell repertoire
that expanded in blood over the 2-yr treatment, persisting 2-
yr after completing the protocol; along with lymphocytes only
detected at the tumor site (16). In this paper, we investigated
in-depth another patient from the same protocol; we were able
to compare for the first time clonotypes from a vaccination site
(VAC-SITE), a C-MTS, and peripheral blood throughout the
CSF-470 immunization protocol.
CASE REPORT
Patient’s 045 Case Presentation and
Treatment
Patient #045 (pt-045) is a 51 year-old Caucasian man, to
whom in January 2016 a primary dorsal epithelioid CM
(1CM) was excised. Its main characteristics were a 2.3mm
Breslow thickness, an intermediate proliferative index (23%
Ki-67+), and non-brisk lymphoid infiltration; no evidence
of ulceration, regression, satellitosis, or vascular invasion
were found (Supplementary Figure 1). One month later, a
right axillary sentinel lymph node (LN) was excised, and a
micrometastasis was found. Pt-045 was therefore at stage-IIIA
(AJCC 8th edition), but radical lymphadenectomy was not
performed. In April 2016, the patient signed the informed
consent and entered the CASVAC-0401 study, being assigned
to the CSF-470 vaccine arm. In August 2016, after receiving
four vaccinations, a CM recurrence on the scar (Scar-CM) was
excised, which displayed scarce CD8+ lymphocyte infiltration
(not shown). The patient continued treatment as per protocol.
In May 2017, after 8 vaccinations and 12 months after starting
treatment, the patient presented an enlarged right-axillary LN
and a thoracic in-transit cutaneous metastasis (C-MTS). A
radical axillary LN resection and a C-MTS was resected; 1/20
metastatic LN was found. In the same surgical procedure, three
vaccination nodules (VAC-SITE), all metabolically active, were
excised at the patient’s decision. After surgery, pt-045 continued
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and completed the 2-yr immunization protocol with the CSF-470
vaccine without further events, and without evidence of disease
36 months from protocol start. In the present study, one VAC-
SITE and the C-MTS were analyzed in detail. Time course of
treatment, as well as the surgical events and blood extractions,
are indicated (Supplementary Figure 2).
RESULTS
Analysis of a CSF-470 VAC-SITE
One of the unanswered questions about repeated vaccinations
with CSF-470 plus BCG and rhGM-CSF is the cellular
composition of the VAC-SITE, since their systematic analysis was
not contemplated per protocol. The three VAC-SITES excised
from pt-045 presented similar histological characteristics; only
one is described here in detail. A highly-inflamed granulomatous
structure was observed, with a necrotic center bordered by
CD11c+ clusters, many of them PD-L1+ (Figures 1A–C). Such
aggregates were surrounded by mostly CD8+ PD1− lymphocytes
(Figures 1E,F), some of them Ki-67+ (Figure 1G). In contrast,
FOXP3+ lymphocytes were scarce (not shown). Abundant and
dispersed CD68+ macrophages were found (Figure 1D). Large
numbers of Langhans multinucleated giant cells (LMGC) were
observed, some of them with more than 10 nuclei, which showed
a typical circular peripheral arrangement (Figures 1H,I); no BCG
bacilli were observed within these cells or elsewhere (not shown).
The site contained D2-40+ lymphatic vessels (Figure 1J);
abundant angiogenesis was revealed by CD34+ blood
vessels (Figure 1K).
Lymphoid Infiltration in a Regional C-MTS
From all the metastases that may signal the recurrence of
melanoma, C-MTS are the most amenable to diagnostic biopsies.
Besides, according to the CASVAC-0401 protocol, loco-regional
metastases may be excised and patients still remain in the
study. Analysis of C-MTS from pt-045 revealed tumor regression
encompassing >90% of the nodule volume; the regression area
was fulfilled with brisk lymphocyte infiltration, mainly composed
of CD8+ T cells (Figure 2A), PD1+ T cells (Figure 2B), few
FOXP3+ Treg cells (Figure 2C), and CD20+ B cells (not shown).
Ki-67+ immune cells were identified in the infiltrated area
(Figure 2D). Also, abundant CD68+ macrophages (Figure 2E)
and dense infiltration of CD11c+ cells (Figure 2F) were detected.
In the areas of brisk lymphocyte infiltration, scarce viable tumor
cells were observed; Granzyme-B staining revealed positive
cytosolic and nuclear granules in tumor cells in these areas of rich
CD8+ lymphocytes infiltration (Supplementary Figure 3). A
small portion of the cutaneous nodule containedMART-1+HLA-
class I+PD-L1− melanoma cells (Figures 2G–I), whereas few
CD8+ PD1+ T cells attached to tumor cells were seen
(Figures 2A,B). Abundant CD34+ blood vessels and D2-40+
lymphatic vessels were seen in the viable tumor area (not shown).
Evidence of T-Cell Response Induced by
the CSF-470 Vaccine
As a measure of the immune stimulation developed during CSF-
470 vaccination, a skin DTH-score was performed at baseline
(PRE) and after administration of each of the 13 vaccine doses;
the score was calculated as described (14). As for most patients
in the CASVAC-0401 study, pt-045 DTH-score increased with
vaccination, evidencing the induction of a memory immune
response to CSF-470 vaccine Ags (Supplementary Figure 4).
In order to characterize the repertoire of T-cell clones present
at the VAC-SITE, recruited at the C-MTS, and their dynamics
in blood during vaccination, CDR3-TCRβ sequencing from
gDNA was performed in VAC-SITE, C-MTS as well as in PBMC
samples obtained before (PBMC-PRE), during and at the end
of the CSF-470 immunization (PBMC-POST-2 and PBMC-
POST-3, respectively) (Supplementary Figure 2). Given the
relative sample sizes used for the TCR sequencing, as expected,
TCRβ repertoire was larger at PBMC samples than at VAC-SITE
and C-MTS samples (Supplementary Figure 5A). Analysis of
productive amino-acidic sequence clonotypes was performed
(Supplementary Tables 1–5, Supplementary Material 1).
Regarding general TCRβ metrics, the cumulative frequency of
the 100 most-frequent peripheral TCRβ clonotypes (TOP100)
was stable in time and amounted to around 10% of total clones;
instead, TCRβ repertoires from the VAC-SITE and the C-MTS
weremore oligoclonal (Supplementary Figure 5B). Accordingly,
plots of cumulative frequency of clones, ordered from highest to
lowest, supported this distribution (Supplementary Figure 5C).
Also, we analyzed in all samples the distribution of redundant
clones, i.e., TCRβ clones with different gene rearrangements
that converge into the same amino-acidic sequence; and
their specific redundancy, the number of rearrangements per
redundant clone. Both VAC-SITE and C-MTS presented a
major cumulative frequency and mean proportion of redundant
clones (Supplementary Figures 5D,E). Notably, TOP100 clones
were enriched in redundant clones in every sample tested
(Supplementary Figure 5F).
We addressed whether the T-cell repertoire found at the VAC-
SITE was related to the C-MTS which appeared during the
immunization protocol, as there might be clonotypes targeting
shared-Ags. Indeed, 1,098 clones were found in common between
the VAC-SITE and the C-MTS (Supplementary Figure 6A),
which represented 37% of the total C-MTS (TIL) clones. Most
of such shared clones were also detected in blood; only 14%
were exclusively detected at tissue (not shown). Remarkably,
the frequency of the shared clonotypes was significantly higher
in C-MTS compared to VAC-SITE (Supplementary Figure 6B)
adding together a cumulative frequency of 42%, suggesting their
biological relevance (Supplementary Figure 6C).
Another relevant question was whether the T-cell clones
recruited at the VAC-SITE and/or the C-MTS persisted in blood
by the end of the 2-yr immunization protocol (PBMC-POST-3),
defined as persistent clones. Of the 1,098 T-cell clones common
to the VAC-SITE and the C-MTS, 70% (773) were detected
in the PBMC-POST-3 sample; 1,965 clones were only shared
between the VAC-SITE and PBMC-POST-3; while 886 clones
were only shared between the C-MTS and PBMC-POST-3;
adding together 3,624 persistent clones (Figure 3A). Persistent
clones made up 88% of PBMC-POST-3 TOP 100 most-frequent
clones (not shown). Clone-tracking patterns were defined to
study PBMC dynamics in blood throughout immunization,
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FIGURE 1 | Analysis of a CSF-470 VAC-SITE tissue. (A–C) Dense clusters of CD11c+ cells were observed at the VAC-SITE, most of them also expressing PD-L1;
(D) Abundant CD68+ macrophages were also present in the area. (E–G) CD8+ lymphocytes were mainly PD1− and many of them were proliferating (Ki67+).
(H,I) Numerous LMGC were observed by HE staining (arrows). (J,K) The VAC-SITE was surrounded by numerous lymphatic and blood vessels (arrows). Original
magnifications = (A,D–G,J,K): 20X; (B,C,H): 100X; (I): 1000X. Scale bars: (A,D–G,J,K) =200µm; (B,C,H) = 100µm; (I) = 20µm.
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FIGURE 2 | Analysis of C-MTS tissue. In the area of tumor regression (upper part of the biopsy), CD8+ (A) and PD-1+ (B) T lymphocytes were mainly present, while
FOXP3+ Treg were scarce (C); these lymphocytes were proliferating as determined by Ki-67+ staining (D). Also, CD68+ macrophages (E) and CD11c Ag-presenting
cells (F) were mainly concentrated in this area. In the lower part of the biopsy, MART-1+ (G) PD-L1− (H) HLA class I + (I) viable tumor cells were observed. Original
magnification = 20X. Scale bars = 200µm.
including persistent clones (Supplementary Figure 7). A
subset of 530 persistent clones (27%) at least doubled their
frequency throughout immunization, so called markedly-
increased frequency clones (MIFC) (Figure 3B). Most circulating
MIFC presented common clonotypes with the VAC-SITE,
although the higher cumulative frequency with VAC-SITE/C-
MTS common clones was found (Figure 3C). Regarding initial
abundance, most MIFC expanded from very-low-frequency
(VLF) clones; however there was a marked-expansion from
pre-existing basal clones for VAC-SITE/C-MTS common
clonotypes (Figure 3D). Regarding redundant clones, they
were preferentially distributed among the persistent common
clones between PBMC-POST-3 and VAC-SITE and/or C-MTS
samples (Figure 3E). Almost all redundant clones varied their
number of rearrangements in time (specific redundancy, not
shown). Indeed, 243 of all persistent clones (13%) at least
doubled their specific redundancy, so called markedly-increased
redundant clones (MIRC) (Figure 3F). 56% of MIRC were
also MIFC (not shown). Accordingly, MIRC presented more
common clonotypes with the VAC-SITE, while the higher
cumulative frequency with common VAC-SITE/C-MTS clones
was found (Figure 3G).
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FIGURE 3 | Analysis of in vivo persistent TCRβ clones following CSF-470 immunization. (A) Venn diagram showing the distribution of common TCRβ clonotypes
between PBMC-POST-3, VAC-SITE, and C-MTS samples from pt-045. (B) Normalized frequency tracking of 2 different clonotypes to illustrate markedly-increased
frequency clones, MIFC. (C) Distribution (%) of persistent MIFC regarding N◦ clones and cumulative frequency in the VAC-SITE/C-MTS compartments. (D) Distribution
of MIFC and subsets regarding procedence from very-low-frequency clones (PRE-VLF) or basal pre-existing clones (PRE > 0). (E) Mean proportion of redundant
clones for each subset within a sample (bootstrap n = 300, 100 iterations); bars with different letters are statistically different (Wilcoxon, p < 0.05). (F) Normalized
specific redundancy tracking of 2 different clonotypes to illustrate normalized markedly-increased redundant clones, MIRC. (G) Distribution (%) of persistent MIFC
regarding N◦ clones and cumulative frequency in the VAC-SITE and/or C-MTS compartments. Samples: PBMC-POST-3 = POST-3 = P03; VAC-SITE = VS;
C-MTS = CM.
Analysis of PBMC Clonotypes Stimulated
in vitro by the CSF-470 Vaccine
Recognition of vaccine Ags by pt-045 lymphocytes increased
markedly during CSF-470 immunization as measured by IFN-γ
ELISPOT (Figure 4A). A memory response from childhood
vaccination was evident in all PBMC samples stimulated with
BCG (not shown). It was of essential interest to characterize
the TCRβ repertoire after in vitro stimulation of PBMC
with vaccine-lysate to determine if certain clonotypes were
preferentially stimulated. Therefore, we exposed PBMC samples
to CSF-470 vaccine-lysate under the same conditions as for
ELISPOT assay and performed TCRβ sequencing analysis
(Supplementary Tables 6–8, Supplementary Material 1,
Supplementary Figure 8A). We found that clonotypes present
in VAC-SITE/C-MTS tissue repertoire presented increased
frequency distribution after in vitro stimulation as compared
to non-tissue related clones (Supplementary Figures 8B–D).
In particular, frequency of persistent clones (those found in
POST-3 sample) was also increased relative to non-persistent
clones after stimulation (Supplementary Figures 8E–G); thus
further analysis was focused on this subset. Persistent TCRβ
clones expanded after in vitro stimulation relative to their
in vivo counterparts in all PBMC samples as seen in paired
graphs (expansion ≥10%) (Figures 4B–D). Distribution of
common persistent- in vitro- expanded clones of PRE, POST-2
and POST-3 blood samples revealed a core of common clones
that expanded the most for all samples (n = 86) (Figure 4E).
This core of clones accounted for 65% of expanded clones in
PRE-sample and about 40–50% in post-vaccination samples
(Figure 4F). Other clonotypes, not found in PRE-sample, were
expanded in POST-2 and POST-3 in vitro stimulated PBMC,
suggesting that additional clonotypes were stimulated after
vaccination (Figure 4F). In all samples, clonotypes from all
VAC-SITE/C-MTS compartments were expanded; the more
abundant clonotypes (higher cumulative frequency) were
those present both at the VAC-SITE and C-MTS (Figure 4G).
For the in vivo TCRβ repertoire (just as obtained from the
patient), we have previously defined a subset of clonotypes
that markedly increased their frequency after vaccination
(MIFC) as compared to PRE sample (Figures 3B–D). Tracking
of these MIFC among all in vitro-expanded clones revealed
that 30% of them were expanded in vitro in response to
vaccine-Ags (Figure 4H). Mainly, VLF clones were expanded in
this experiment.
Finally, paired-specific redundancy of in vitro-stimulated
clones was increased relative to their in vivo counterparts
(Figures 4I–K); 27% of in vivo MIRC were expanded
in vitro (not shown).
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FIGURE 4 | Analysis of persistent in vitro expanded TCRβ clones with CSF-470 vaccine Ags. (A) PBMC were stimulated in vitro (iv) with CSF-470-vaccine lysate and
evaluated IFN-γ release by ELISPOT assay. Controls: PBMC with only culture medium (–), and with OKT3 plus PHA (+). (B–D) Paired-frequency of persistent
iv-expanded TCRβ clonotypes relative to their in vivo counterpart. (E) Venn diagram distribution of common persistent iv-expanded clones between PRE, POST-2,
and POST-3 samples (expansion ≥ 10%). (F) Cumulative frequency distribution of common iv-expanded clones between the different samples. (G) N◦ and cumulative
frequency distribution of iv-expanded clones in VAC-SITE/C-MTS compartments. (H) Distribution of in vivo MIFC regarding their in vitro frequency-expansion (iv+, iv–)
and their initial abundance (pre-existing basal clones; PRE > 0, and very-low-frequency clones, VLF), in VAC-SITE/C-MTS compartments. (I–K) Paired-specific
redundancy of iv-expanded clones relative to their in vivo counterpart. Samples: PRE = P0 = PBMC-PRE; POST-2 = P2 = PBMC-POST-2; POST-3 = P3 =
PBMC-POST-3. IV; iv: in vitro. All Wilcoxon test, ****p < 0.0001.
DISCUSSION
In this study, we examined a metabolically-active chronic VAC-
SITE and correlated its lymphoid infiltrate with that present
in a C-MTS that appeared during immunization. We also
analyzed the clonal TCRβ dynamics in blood throughout CSF-
470 immunization protocol. Since BCG was an adjuvant in
our CSF-470 cellular vaccine, we asked if the strong BCG
immunogenicity was detrimental to the immune response toward
tumor Ags. Previous work from our group suggested that this
was not the case, since a potent Th1 response toward vaccine-
Ags was obtained (14, 17). In pt-045, vaccination induced chronic
granulomas resembling chronic M. tuberculosis granulomas (18,
19), with a central, necrotic, and caseous core surrounded by a
lymphoid structure. A highly-organized structure of clusters of
CD11c+ cells co-expressing PDL-1 was observed, suggesting a
role in local Ag presentation. CD8+ lymphocytes and CD68+
macrophages were abundant and intersparsed among CD11c+
clusters, whereas PD1+ and FOXP3+ lymphocytes were scarce.
The maturity of the granuloma was corroborated by the presence
of characteristic LMGC, devoid of BCG bacilli. Notably, in a
previous, acute CSF-470 VAC-SITE which developed after only
one immunization, LMGC were scarce and only had few nuclei
(20). Although the function of LMGC remains to be defined,
in vitro experiments suggest that they arise after interaction
between bacterial lipomannan and macrophages (21). Lay et al.
showed in an experimental granuloma system that LMGC
with a large number of nuclei were unable to phagocytose M.
tuberculosis but retained Ag-presentation capacity (22), and Byrd
proposed that LMGC induced by IFN-γ/IL-3 are a hallmark of
an effective immune response in mycobacterial infection (23).
Previous in vitro experiments demonstrated that BCG-induced
strong-release by monocytes of the pro-inflammatory cytokines
TNF-α and Il-1β, and that such release was tempered by the
presence of vaccine irradiated-tumor cells (24). We suggest that
the final granuloma structure at VAC-SITE is shaped by the
interaction among BCG, irradiated CSF-470 cells and incoming
immune cells.
Although blood CD4+ and CD8+ T lymphocyte numbers
did not increase in periphery throughout vaccination (14), we
observed brisk-lymphocyte infiltration in the C-MTS, with a
markedly increased relative to the primary tumor, confirming
a previous observation (16). Such increase in C-MTS TIL is
important, since tissue microarrays performed on excisional
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biopsies from 95 patients revealed that brain and skin metastases
were less infiltrated by TIL than other sites (25), and coincides
with another analysis of 192CM metastases, in which 159
patients lacked an inflammatory component and only 33 patients
presented a mild-to-moderate inflammatory component (26).
It has been reported that TILs in melanoma have a positive
prognostic value of a relevant immune response toward tumor
cells (27). Also, TILs have been shown to be reactive against
shared tumor antigens and neoantigens (28). Besides, increases
in the DTH-score and T-cell reactivity against vaccine Ags by
ELISPOT during vaccination was observed for most CSF-470
vaccinated patients (14).
Analysis of the CDR3-TCRβ is commonly used as a
molecular barcode as it allows analyzing the distribution of
T-cell clones among the different body compartments and
their dynamics. However, additional diversity is achieved by
different combinations of α and β chains giving rise to the
full functional TCR, with the potential to cover the broad
repertoire of antigens (29). We analyzed if the T-cell repertoire
present at the VAC-SITE was related to that infiltrating the
C-MTS. Indeed, 37% of C-MTS TIL TCRβ clonotypes were
common to those found at the VAC-SITE and had expanded
in frequency. The majority of shared clones persisted in blood
by the end of the CASVAC-0401 protocol (PBMC-POST-
3), suggesting the induction and persistence of a specific
immune response. Such persistent clonotypes remained at
high frequency in blood; most-frequent clonotypes are usually
related to a relevant biological role (30). Persistent MIFC
were also detected in both VAC-SITE/C-MTS compartments,
suggesting the expansion of clonotypes recognizing common
as well as private Ags. Importantly, increased MIFC expansion
was detected for common VAC-SITE/C-MTS clones derived
from peripheral basal pre-existing clones, suggesting that such
clonotypes might recognize shared melanocyte-differentiation
Ags and cancer-testis Ags, known to be expressed by the CSF-470
vaccine (14).
In vitro stimulation of PBMC obtained before (PRE) and
after vaccination with CSF-470 lysate expanded 30% of persistent
MIFC found at VAC-SITE/C-MTS. Persistent clones previously
found to be shared only with C-MTS were also expanded,
suggesting that vaccine Ags induced a broader TCRβ repertoire
than that detected in the VAC-SITE. Other persistent MIFC
expanded in vivo were not expanded in vitro; these clonotypes
might be recognizing private Ags present not in the vaccine.
In recent work, TCRβ sequencing was used to address the
origin of clinically relevant T-cell clones following adoptive
cell therapy, and it was found that VLF clones expanded and
persisted in time in those patients who achieved a complete
response (31). Accordingly, among persistent clones we found
that 75% of MIFC were also VLF clones which emerged
during immunization.
Long-term persistence of vaccine-induced T-cell repertoires
was shown by TCR clonotyping and multimer staining in other
vaccination systems. Evidence was shown for peptide-based
vaccines with MART-1 (32, 33) and MAGE (34) Ags for
melanoma; with cancer-testis Ag for lung cancer (35); with
glypican-3 Ag for hepatocellular carcinoma (36), and with
allogeneic cell-vaccines combined with ICKB for pancreatic
ductal adenocarcinoma (37). Finally, persistent TCR repertoires
were shown in dendritic cell-based personalized vaccine
targeting neoantigens and gp100 peptides (38), and in TRP2
mRNA-electroporated Langerhans cells in phase I trials for
melanoma (39).
Our results from pt-045 showed that CSF-470 immunization
induced the expansion and emergence of a T-cell repertoire able
to infiltrate tumor sites, as described previously for pt-006 (16);
with analysis for the first time of VAC-SITE clonotypes. That
new clonotypes still appeared by the end of the immunization
protocol suggests that repeated prolonged vaccination is useful.
Interestingly, when analyzing the distribution of redundant
clonotypes in all samples, we found that VAC-SITE and C-MTS
presented high specific redundancy, with even >20 TCRβ clones
with different nucleotide sequences converging to the same
aminoacidic sequence. This might have functional implications
at the VAC-SITE, where Ag-stimulation is being seeked, as well as
in the C-MTS, where effective T-cell effector function is desired.
These results support the hypothesis that biologically relevant
T-cell clones might expand through the proliferation of several
redundant TCRβ clones, underlying a functional antigenic
selection. Noticeably, the proportion of redundant clones in
PBMC-POST-3 sample was preferentially distributed into those
shared either with the VAC-SITE and/or the C-MTS. Clonotypes
also exhibited increased specific redundancy when stimulated
in vitro with the vaccine lysate. Accordingly, all subsets
of persistent clones presented markedly-increased redundant
clones, prevailing expansion of those MIRC in common with the
VAC-SITE/C-MTS. Therefore, either emergence or expansion
of persistent clones induced throughout CSF-470 immunization
might stem from the proliferation of clones as well as from
an increase in their specific redundancy. It is our goal in
the near future to perform NGS sequencing of this patient’s
tumor to predict neo-Ags and to test PBMC reactivity both
to common and private peptide-Ags throughout the CSF-470
vaccine immunization protocol. It would be most interesting to
analyze TCR repertoires at the antigen-specific level, tracking
their distribution at the VAC-SITE and the C-MTS as well as
their changes in frequency and redundancy in comparison to the
present work.
CONCLUSION
In this case report of pt-045 from CASVAC-0401 protocol, we
found that immunization with the CSF-470 vaccine plus BCG
and rhGM-CSF induced an immune repertoire of T lymphocytes
at the VAC-SITE, with a related increased immune infiltration
in a regional C-MTS, resulting in the expansion of Ag-boosted
T-cell clones which persisted in blood by the end of the
2-yr vaccination.
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